Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

Leuk Lymphoma. 2022 Mar;63(3):738-742. doi: 10.1080/10428194.2021.2005045. Epub 2021 Nov 16.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Humans
  • Myeloid Differentiation Factor 88 / genetics
  • Piperidines
  • Receptors, CXCR4 / genetics
  • Waldenstrom Macroglobulinemia* / diagnosis
  • Waldenstrom Macroglobulinemia* / drug therapy
  • Waldenstrom Macroglobulinemia* / genetics

Substances

  • CXCR4 protein, human
  • Myeloid Differentiation Factor 88
  • Piperidines
  • Receptors, CXCR4
  • ibrutinib
  • Adenine